Erythropoiesis stimulating agents and other growth factors in low-risk MDS

Best Practice and Research: Clinical Haematology

Volumn 26, Issue 4, 2013, Pages 401-410

  Hellström Lindberg, Eva ^a   Van De Loosdrecht, Arjan ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b University of Amsterdam   (Netherlands)

Author keywords

anemia; erythropoietin; growth factors; myelodysplasia

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; FIBRINOLYTIC AGENT; GROWTH FACTOR; HEMOPOIETIC GROWTH FACTOR; HROMBOMIMETIC AGENT; UNCLASSIFIED DRUG;

ANEMIA; BLOOD TRANSFUSION; FLOW CYTOMETRY; HEMATOPOIESIS; HUMAN; LONG TERM CARE; MITOCHONDRIAL MEMBRANE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; THERAPY EFFECT; TREATMENT RESPONSE;

ANEMIA; ERYTHROPOIETIN; GROWTH FACTORS; MYELODYSPLASIA;

APOPTOSIS; BLOOD TRANSFUSION; ERYTHROID CELLS; ERYTHROPOIETIN; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MYELODYSPLASTIC SYNDROMES; QUALITY OF LIFE; RISK FACTORS; TIME FACTORS;

EID: 84893736014     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2013.09.007     Document Type: Review

References (44)

1. P.L. Greenberg, H. Tuechler, and J. Schanz et al. Revised international prognostic scoring system for myelodysplastic syndromes Blood 120 2012 2454 2465
2. L. Malcovati, M.G. Della Porta, and C. Strupp et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based prognostic scoring system (WPSS) Haematologica 96 2011 1433 1440
3. L. de Swart, A. Smith, and P. Fenaux et al. Early mortality in 1000 newly diagnosed MDS patients with low- and Intermediate-1 risk MDS in the European leukemianet MDS (EUMDS) Registry Blood 120 2012 3830 (ASH Annual Meeting Abstracts)
4. Ejerblad E, for the Nordic MDS Group. Report nr 1 from the Swedish MDS-registry (www.nmds.org/).
5. L. Malcovati, U. Germing, and A. Kuendgen et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes J Clin Oncol 25 2007 3503 3510
6. H. Nilsson-Ehle, G. Birgegård, and J. Samuelsson et al. Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a hemoglobin level of 120 g/l with darbepoetin alfa ± filgrastim, or erythrocyte transfusions Eur J Haematol 87 2011 244 252
7. C. Kelaidi, O. Beyne-Rauzy, and T. Braun et al. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM Ann Hematol 92 2013 621 631
8. M. Malcovati, E. Hellström-Lindberg, and E. Bowen et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet Blood 2013 Aug 26 [Epub ahead of print]
9. D.T. Bowen, and E. Hellstrom-Lindberg Treatment of anemia in myelodysplastic syndromes J.M. Bennet, The myelodysplastic syndromes in pathobiology and clinical management 2002 Marcel Dekker Inc New York 345 372
10. M.G. Vander Heiden, and C.B. Thompson Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis? Nat Cell Biol 1 1999 e209 e216
11. H. Wajant The Fas signaling pathway: more than a paradigm Science 296 2002 1635 1636
12. R. De Maria, U. Testa, and L. Luchetti et al. Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis Blood 93 1999 796 803
13. R. Tehranchi, B. Fadeel, and A.M. Forsblom et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors Blood 101 2003 1080 1086
14. B.L. Ebert, J. Pretz, and J. Bosco et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen Nature 451 2008 335 339
15. J.L. Barlow, L.F. Drynan, and D.R. Hewett et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome Nat Med 16 2010 59 66
16. A.G. Kulasekararaj, A.E. Smith, and S.A. Mian et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis Br J Haematol 160 2013 660 672
17. E. Papaemmanuil, M. Cazzola, and J. Boultwood et al. Chronic myeloid disorders working group of the international cancer genome consortium. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts N Engl J Med 365 2011 1384 1395
18. M. Nikpour, C. Scharenberg, and A. Liu et al. The transporter gene ABCB7 is an important mediator in the phenotype of acquired refractory anemia with ring sideroblasts Leukemia 27 2013 889 896
19. E. Frisan, J. Vandekerckhove, and A. de Thonel et al. Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes Blood 119 2012 1532 1542
20. R. Tehranchi, B. Fadeel, and J. Schmidt-Mende et al. The anti-apoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations Clin Cancer Res 11 2005 6291 6299
21. M. Nikpour, A. Pellagatti, and A. Liu et al. Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF Br J Haematol 149 2010 844 854
22. B.D. Cheson, P.L. Greenberg, and J.M. Bennett et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia Blood 108 2006 419 425
23. M. Jädersten, S. Montgomery, and I. Dybedal et al. Long-term outcome of treatment with Granulocyte-CSF and erythropoietin for the anemia of myelodysplastic syndromes Blood 106 2005 803 811
24. S. Park, S. Grabar, and C. Kelaidi et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience Blood 111 2008 574 582
25. S. Park, C. Kelaidi, and R. Sapena et al. Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients Leuk Res 34 2010 1430 1436
26. R.S. Negrin, R. Stein, and K. Doherty et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy Blood 87 1996 4076 4081
27. N. Casadevall, P. Durieux, and S. Dubois et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial Blood 104 2004 321 327
28. E. Balleari, E. Rossi, and M. Clavio et al. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study Ann Hematol 85 2006 174 180
29. P.L. Greenberg, Z. Sun, and K.B. Miller et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996) Blood 114 2009 2393 2400
30. E. Hellstrom-Lindberg, N. Gulbrandsen, and G. Lindberg et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life Br J Haematol 120 2003 1037 1046
31. T.M. Westers, R. Ireland, and W. Kern et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European leukemianet working group Leukemia 26 2012 1730 1741
32. T.M. Westers, C. Alhan, and M.E.D. Chamuleau et al. Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment Blood 115 2010 1779 1784
33. E. Frisan, P. Pawlikowska, and C. Pierre-Eugene et al. p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes Haematologica 95 2010 1964 1968
34. V. Moyo, P. Lefebvre, and M.S. Duh et al. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis Ann Hematol 87 2008 527 536
35. M. Jädersten, L. Malcovati, and A. Porwit-McDonald et al. Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need J Clin Oncol 26 2008 3607 3613
36. C. Kelaidi, S. Park, and R. Sapena et al. Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents Leukemia 27 2013 1283 1290
37. A. List, G. Dewald, and J. Bennett et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion N Engl J Med 355 2006 1456 1465
38. P. Fenaux, A. Giagounidis, and D. Selleslag et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q Blood 118 2011 3765 3776
39. A. Kuendgen, M. Lauseker, and A.F. List et al. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with low- or Intermediate-1-risk MDS with del(5q): a comparative analysis Leukemia 27 2013 1072 1079
40. E.M. Sloand, C.O. Wu, and P. Greenberg et al. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy J Clin Oncol 26 2008 2505 2511
41. J. Neukirchen, S. Blum, and A. Kuendgen et al. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes Eur J Haematol 83 2009 477 482
42. S.J. Stanworth, L.J. Estcourt, and G. Powter et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers N Engl J Med 368 2013 1771 1780
43. H. Kantarjian, P. Fenaux, and M.A. Sekeres et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia J Clin Oncol 28 2010 437 444
44. A. Giagounidis, G.J. Mufti, and H.M. Kantarjian et al. Treatment with the thrombopoietin (TPO)-receptor agonist romiplostim in thrombocytopenic patients (Pts) with low or intermediate-1 (Int-1) risk myelodysplastic syndrome (MDS): results of a randomized, double-blind, placebo(PBO)-controlled study vol. 118 2011 117 (ASH Annual Meeting Abstracts)